Grupo Ferrer Internacional S.A. Successfully Completes an Absorption, Tolerability and Safety Study in Juveniles as Young as Two Months of Age for Novel Antibacterial Compound Ozenoxacin
10/5/2012 11:00:15 AM
More...
|
Ferrer Internacional Initiates Phase III Clinical Studies for Novel Antibacterial Compound, Ozenoxacin, in Development as a Topical Treatment for Impetigo and Other Infectious Dermatological Conditions
1/19/2012 10:27:03 AM
More...
|
APR Applied Pharma Research S.A. and Labtec GmbH Enter Into Exclusive Licensing Agreement With Ferrer Internacional for the Registration and Marketing of Donepezil Oral Dispersible Film in Spain, Portugal and Germany
10/1/2010 8:57:20 AM
More...
|